AI assistant
KANABO GROUP PLC AGM Information 2023
4978_dva_2023-06-30_3d2ff682-6332-463d-8305-875393c382cf.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6041E
Kanabo Group PLC
30 June 2023
30 June 2023
Kanabo Group Plc
("Kanabo" or the "Company")
Result of AGM
Kanabo Group Plc (LSE:KNB), the patient focused healthcare technology and medicinal cannabis company, announces that at the Annual General Meeting ("AGM") held earlier today thirteen resolutions were duly passed. The numbers of votes for each resolution are presented below:
| Resolution (No. as noted on proxy form) | Total For (i) | Total Against | Withheld (ii) | ||
| No. of votes | % of vote |
No. of votes | % of vote |
No. of votes | |
| Resolution 1 | 231,148,817 | 99.93% | 162,363 | 0.07% | 74,145 |
| Resolution 2 | 230,958,946 | 99.90% | 230,317 | 0.10% | 196,062 |
| Resolution 3 | 161,657,876 | 99.88% | 197,595 | 0.12% | 69,529,854 |
| Resolution 4 | 223,079,901 | 96.45% | 8,201,867 | 3.55% | 103,557 |
| Resolution 5 | 223,081,901 | 96.46% | 8,198,729 | 3.54% | 104,695 |
| Resolution 6 | 223,091,027 | 96.46% | 8,189,603 | 3.54% | 104,695 |
| Resolution 7 | 231,103,813 | 99.91% | 199,779 | 0.09% | 81,733 |
| Resolution 8 | 223,053,034 | 96.44% | 8,245,185 | 3.56% | 87,106 |
| Resolution 9 (iii) | 153,592,369 | 66.41% | 77,697,479 | 33.59% | 95,477 |
| Resolution 10 | 231,033,085 | 99.86% | 313,000 | 0.14% | 39,240 |
| Resolution 11 (iii) | 223,042,578 | 96.41% | 8,303,507 | 3.59% | 39,240 |
| Resolution 12 | 222,934,014 | 96.41% | 8,304,818 | 3.59% | 146,493 |
| Resolution 13 | 231,033,617 | 99.89% | 254,406 | 0.11% | 97,302 |
| Resolution 14 (iii) | 223,042,110 | 96.41% | 8,302,150 | 3.59% | 41,065 |
(i) The "For" Proxy vote includes those giving the Chair of the AGM discretion
(ii) A vote "Withheld" is not a vote in law and is not included in the proxy votes "For" or "Against" the resolution
(iii) Special resolution
The full text of the resolutions can be found in the Notice of Annual General Meeting, which is available on the Company's website at: https://www.kanabogroup.com/investors/
For further information, please visit http://www.kanabogroup.com/ or contact the following:
Enquiries:
| Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial Officer Ian Mattioli, Non-Executive Chair of the Board |
via Vigo Consulting +44 (0)20 7390 0230 |
| Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker/ Lucy Williams / Charles Goodfellow |
+44 (0)20 7469 0930 |
| Vigo Consulting (Financial Public Relations/Investor Relations) Jeremy Garcia / Fiona Hetherington / Verity Snow [email protected] |
+44 (0)20 7390 0230 |
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com for more information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGEADKEDDFDEFA